Ring Therapeutics
Cambridge
About Ring Therapeutics
Ring Therapeutics is a multi-product platform company focused on discovering and developing Anellovector therapeutics to unlock the full potential of gene therapy. Founded by Flagship Pioneering, Ring is pioneering the first redosable and targetable gene therapy platform by harnessing the biology of the human commensal virome. The company is expanding the applications of gene therapy beyond gene replacement, enabling a much wider array of modalities and mechanisms to treat previously inaccessible diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $253.5M
- Funding stage: Late Stage Venture
- Last round: Series C (Mar 2023)
- Website: ringtx.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/ring-therapeutics-11373 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.